patritumab deruxtecan

Ask MedXY AI

Latest news

Tag

NeurologyAntibody-drug conjugateBrain Metastases

Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial

By MedXY|Oct 31, 2025

The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.

Clinical UpdatesAntibody-drug conjugateHER3-DXd

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY|Oct 7, 2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Clinical Updatesantibody-drug conjugatespatritumab deruxtecan

Patritumab Deruxtecan Shows Promising Efficacy in HR+HER2− Advanced Breast Cancer After CDK4/6 Inhibitor Failure: Insights from ICARUS-BREAST01 Phase 2 Trial

By MedXY|Oct 6, 2025

The ICARUS-BREAST01 phase 2 trial demonstrated patritumab deruxtecan’s efficacy and manageable safety in HR+HER2− metastatic breast cancer post-CDK4/6 inhibitors, highlighting key biomarkers linked to response and resistance.